The Protein Myth: Our Obsession With Protein and How It Is Killing US

Houston Methodist

G. Davis

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

GI and Hepatic Complications of Cancer Immunotherapy

Michigan Medicine

R. Fontana

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

West Virginia State Rheumatology Society

J. Bustamante

Safety and Monitoring Considerations in Systematic Therapy

Masterclasses in Dermatology

J. Cohen

History of Cancer and Its Treatment: What Will It Take to Cure?

University of Colorado Cancer Center

C. Lieu

ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based GvHD Pr…

2024 ASCO® Annual Meeting Insights Hub

M. Al Malki

How to Minimize and Manage Checkpoint Inhibitors Adverse Cardiac Eve…

University of Colorado Department of Medicine

L. Kondapalli

Developing Novel Therapeutics for Brain Tumors in the Age of Genomic…

Penn Medicine's 11th Neuro-Oncology Brain Tumor Symposium 2024

E. Galanis

Top Risk Factors for Cancer by Sex and What to Do About It

MedCram

R. Seheult

Selection and Sequencing of Chronic GVHD Therapy

Rush University Medical Center

S. Kosuri

Biomarkers in Immuno-Oncology: Road to Personalized Immunotherapy

Penn Medicine's 11th Neuro-Oncology Brain Tumor Symposium 2024

C. Jackson

GVHD: Importance of Early Detection and Management

Ernst Holler

The Immunology of Immune Cell Cancers

Tanaya Shree

The Obesity-Cancer Link: Current Hypotheses for Causal Connection

UCLA Health

V. Surampudi

Overview of Hematopoietic Cell Transplantation

Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

R. Salit

Axatilimab in Chronic GVHD: Updates From the AGAVE-201 Study

Zachariah DeFilipp

Treating Fibrosis and Inflammation in GvHD

Pooja Khandelwal

Chronic GVHD: A Case-Based Discussion

Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

L. Perry

Steroid-Refractory GvHD Management: When to Switch From Steroids

Giuseppe Francesco Milone